FIG. 2.

Efficacy of EB in vivo. Mice (10 per group) were intranasally inoculated with PBS (▪; control), untreated HK/156 virus (□; 10⁴ TCID₅₀), or EB-d (○; 2 mM)-treated HK/156 virus and monitored for morbidity. Additionally, 10 mice per group were infected with HK/156 and then treated with 2 mM EB-d (•) or 40 mg/kg rimantadine (▴) at 6 hpi and then daily for 5 dpi. Results are representative of four separate experiments. (A) Mice were observed daily for morbidity and clinical signs of illness through an 11-day observation period. (B) On days 2 (solid bars) and 4 (open bars) postinfection, three mice from each group were sacrificed, lungs were harvested, and viral titers were determined from pooled homogenates by TCID₅₀ analysis on MDCK cells. The results represent the means of triplicate determinations. *, statistical significance (P < 0.01).